Sapphire 3 CTO Study

Coronary Artery Disease Clinical Trial

Official title:

Sapphire 3 - A Prospective, Open Label, Multi-center, Single Arm, Observational Study Designed to Evaluate the Acute Safety and Device Performance of the Sapphire 3 0.85-1.25 mm Coronary Dilatation Catheter in Predilatation of Chronic Total Occlusion (CTO) Lesions During Percutaneous Coronary Intervention.

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT06358508
• Other study ID #: VP-0786
• Status: Not yet recruiting
• Phase: N/A
• Start date: June 2024
• Est. completion date: July 2025

Study information

• Verified date: April 2024
• Source: OrbusNeich
• Contact: Debbie Morrell, MSME
• Phone: 954-343-6467
• Email: dmorrell[@]orbusneich.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

A prospective, open label, multi-center, single arm, observational study designed to evaluate the acute safety and device performance of the Sapphire 3 0.85, 1.0 and 1.25mm diameter coronary dilatation catheter in predilatation of Chronic Total Occlusion (CTO) lesions during percutaneous coronary intervention.

One hundred seventy (170) subjects will be enrolled with a target of one hundred fifty-three (153) evaluable subjects by the angiographic core laboratory at up to 15 clinical sites with the Sapphire 3 0.85, 1.0 and 1.25mm diameter PTCA dilatation catheter to pre-dilate CTO lesions in coronary arteries during their index procedure. All subjects will be screened according to the protocol inclusion and exclusion criteria and will be followed through study completion, which is defined as 24-hours post-procedure or hospital discharge, whichever comes first.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 170
• Est. completion date: July 2025
• Est. primary completion date: July 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Clinical Inclusion Criteria:

1. Subject is = 18 years of age.

2. Subject or a legally authorized representative must provide written informed consent prior to any study related procedures.

3. Subject must agree not to participate in any other clinical study during hospitalization for the index procedure that would interfere with the endpoints of this study.

4. Subjects must have a single or double vessel coronary artery disease and clinical evidence of ischemic heart disease, such as stable / unstable angina or silent ischemia attributed to the CTO target vessel and is scheduled for clinically indicated percutaneous revascularization with planned stent placement during this index procedure.

Angiographic Inclusion Criteria

5. Subject must have at least one de novo or restenotic lesion in native coronary arteries with Thrombolysis In Myocardial Infarction (TIMI) flow grade of 0 or 1 and is estimated to be at least 3 months in duration by clinical, angiographic, or electrocardiographic criteria.

6. A maximum of two lesions, including at least one target lesion, in up to two coronary arteries.

7. Treatment of non-target lesion, if any, must be completed prior to treatment of target lesion and must be deemed a clinical angiographic success by visual assessment.

8. The Target lesion is intended for stent placement during this index procedure.

Clinical Exclusion Criteria:

1. Subject with a known hypersensitivity or contraindication to aspirin, heparin, bivalirudin, anti-platelet medications, or sensitivity to contrast media which cannot be adequately pre-medicated.

2. Evidence of acute myocardial infarction (MI) within 72 hours prior to the intended treatment defined as CK-MB or troponin greater than 1X the upper limit of normal (ULN).

3. Subject with known pregnancy or is nursing. Women of child- bearing potential should have a documented negative pregnancy test within 7 days before index procedure.

4. Planned or actual target lesion treatment prior to the use of the Study Device with an unapproved device, atherectomy, laser, cutting balloon or thrombectomy during the index procedure.

5. A serum creatinine level > 2.0 mg/dl within seven days prior to index procedure.

6. Cerebrovascular accident (CVA) within the past 6 months.

7. Active peptic ulcer or active gastrointestinal (GI) bleeding within the past 6 months.

8. Subject has a known left ventricular ejection fraction (LVEF) <30% (LVEF may be obtained at the time of the index procedure if the value is unknown, if necessary).

Angiographic Exclusion Criteria

9. More than two lesions requiring treatment.

10. Unprotected left main coronary artery disease. (Greater than 50% diameter stenosis).

11. Coronary artery spasm of the target vessel in the absence of a significant stenosis.

12. Target lesion with angiographic presence of probable or definite thrombus of TIMI thrombus grade 3 or 4.

13. By visual estimation, target lesion involves a bifurcation requiring treatment with more than one stent or pre-dilatation of a side branch >2.25 mm in diameter.

14. Previous coronary interventional procedure of any kind within the 30 days prior to the procedure in the target vessel.

15. Target vessel with a patent bypass graft from prior coronary bypass surgery.

16. Previous stenting (drug-eluting or bare metal) in the target vessel unless all the following conditions are met:

• It has been at least 9 months since the previous stenting.

• That target lesion is at least 15 mm away from the previously placed stent. Total occlusions involving an in-stent segment are excluded.

• The previously stented segment (stent plus 5 mm on either side) has no more than 40% diameter stenosis.

17. Non-target lesion to be treated during the index procedure meets any of the following criteria:

• Located within a bypass graft (venous or arterial)

• Left main location

• Chronic total occlusion (CTO)

• Is moderately to severely calcified.

• Involves a bifurcation (e.g., bifurcations requiring treatment with more than 1 stent)

• Treatment not deemed a clinical angiographic success

Related Conditions & MeSH terms

• Arteriosclerosis
• Cardiovascular Diseases
• Chronic Total Occlusion
• Chronic Total Occlusion of Coronary Artery
• Coronary Artery Disease
• Coronary Disease
• Heart Diseases
• Ischemia
• Myocardial Ischemia

Intervention

Device:
• Sapphire 3 Coronary Dilatation Catheter
To pre-dilate Chronic Total Occlusion (CTO) lesions in coronary arteries during the subject's index procedure with Sapphire 3 0.85mm, 1.0mm, and 1.25mm diameter Coronary Dilatation Catheters.

Locations

Country	Name	City	State
n/a

Sponsors (2)

Lead Sponsor	Collaborator
OrbusNeich	Avania

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of Participants With Device Procedural Success	Device procedural success consisting of the following: Successful delivery, inflation, deflation and withdrawal of the study balloon and after the guidewire has successfully crossed the CTO lesion into the true lumen of the vessel; No evidence of vessel perforation or dissections (Grade C or higher) related to the study balloon; Final TIMI flow grade of II or III at the conclusion of the PCI procedure	24 hours post-procedure or hospital discharge, whichever comes first
Secondary	Number of Participants With In-hospital Major Adverse Cardiac Events (MACE)	In-hospital Major Adverse Cardiac Events (MACE) which is a hierarchical composite of: All death (cardiac and non-cardiac); Myocardial infarction (MI); Target Lesion Revascularization (TLR)	24 hours post-procedure or hospital discharge, whichever comes first
Secondary	Number of Deaths (Cardiac and Non-Cardiac)	All death (cardiac and non-cardiac)	24 hours post-procedure or hospital discharge, whichever comes first
Secondary	Number of Participants With Myocardial Infarctions (MI)	Myocardial Infarctions (MI)	24 hours post-procedure or hospital discharge, whichever comes first
Secondary	Number of Participants With Target Lesion Revascularization (TLR)	Target Lesion Revascularization (TLR)	24 hours post-procedure or hospital discharge, whichever comes first
Secondary	Number of Participants With In-hospital stent thrombosis (ST) Within the Target Vessel	In-hospital stent thrombosis (ST) Within the Target Vessel	24 hours post-procedure or hospital discharge, whichever comes first
Secondary	Number of Participants With Clinically Significant Arrhythmias (Requiring Intervention)	Clinically Significant Arrhythmias (Requiring Intervention)	24 hours post-procedure or hospital discharge, whichever comes first
Secondary	Number of Participants With Absence of Sapphire 3 Study Balloon Rupture	Absence of Sapphire 3 Study Balloon Rupture	Peri-procedural
Secondary	Number of Participants That Had Improvement in the Minimum Lumen Diameter (MLD) following use of Sapphire 3 catheter (independently measured by the Angiographic Core Lab using QCA)	Improvement in Minimum Lumen Diameter (MLD) following use of Sapphire 3 catheter (measured by QCA).; Improvement in MLD is defined as MLD post use of Sapphire 3 as greater than MLD from baseline.	Peri-procedural
Secondary	Number of Participants With Technical Success	Technical Success defined as Achievement of TIMI grade II or greater antegrade flow in all =2.5-mm distal branch(es) with <30% residual stenosis of the target CTO lesion at the completion of the procedure, (independently measured by the Angiographic Core Lab using QCA).	Peri-procedural